Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer.

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2011.05.005 ◽

2011 ◽

Vol 47 (14) ◽

pp. 2091-2098 ◽

Cited By ~ 16

Author(s):

D. Amadori ◽

C. Milandri ◽

G. Comella ◽

S. Saracchini ◽

S. Salvagni ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽

A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80420-9 ◽

2006 ◽

Vol 4 (2) ◽

pp. 165

Author(s):

M. Zilli ◽

De Tursi ◽

C. Carella ◽

E. Ricevuto ◽

P. Marchetti ◽

...

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

Oncology Research and Treatment ◽

10.1159/000080363 ◽

2004 ◽

Vol 27 (5) ◽

pp. 441-446 ◽

Cited By ~ 7

Author(s):

B. Mlineritsch ◽

P. Mayer ◽

C. Rass ◽

E. Reiter ◽

G. Russ ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

P101 A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer

The Breast ◽

10.1016/s0960-9776(07)70161-3 ◽

2007 ◽

Vol 16 ◽

pp. S41

Author(s):

M. De Tursi ◽

C. Carella ◽

E. Ricevuto ◽

A. Gennari ◽

C. Orlandini ◽

...

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer

Oncology Research and Treatment ◽

10.1159/000180915 ◽

2009 ◽

Vol 32 (1-2) ◽

pp. 18-24 ◽

Cited By ~ 7

Author(s):

Brigitte Mlineritsch ◽

Renate Schabel-Moser ◽

Johannes Andel ◽

Michael Fridrik ◽

Martin Moik ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First‐Line Treatment for HER‐2‐positive Locally Recurrent or Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2011-0344 ◽

2012 ◽

Vol 17 (4) ◽

pp. 469-475 ◽

Cited By ~ 34

Author(s):

Miguel Martín ◽

Anatoly Makhson ◽

Joseph Gligorov ◽

Mikhail Lichinitser ◽

Ana Lluch ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽

Locally Recurrent ◽

Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet)

Annals of Oncology ◽

10.1016/s0923-7534(20)32976-8 ◽

2012 ◽

Vol 23 ◽

pp. ix142

Author(s):

M. Andersson ◽

J.M. Lopez-Vega ◽

L. Del Mastro ◽

T. Petit ◽

L. Mitchell ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2216-8 ◽

2013 ◽

Vol 72 (2) ◽

pp. 429-435 ◽

Cited By ~ 4

Author(s):

Maged Mansour ◽

Cynthia Mourad

Keyword(s):

Breast Cancer ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Oral Vinorelbine ◽

Her 2 ◽

413 POSTER A multicenter phase II study of Epirubicin (E) with low-dose herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80711-6 ◽

2005 ◽

Vol 3 (2) ◽

pp. 116

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdh218 ◽

2004 ◽

Vol 15 (6) ◽

pp. 891-895 ◽

Cited By ~ 30

Author(s):

A. Alexopoulos ◽

M.V. Karamouzis ◽

H. Stavrinides ◽

A. Ardavanis ◽

K. Kandilis ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽